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Context. Data regarding palliative sedation at home in dying patients are
lacking.
Objectives. To describe the frequency, indication, and modality of palliative
sedation (PS) in patients followed at home.
Methods. A retrospective analysis of home care cancer patients was performed.
Patients who received PS before dying were selected and information about
epidemiologic characteristics, indications,duration,drugs, andoutcomeswas collected.
Results. Of 370 medical charts of patients who died at home, 49 patients
received PS before dying. PS was proposed by the team, relatives, or both in
63.3%, 4.1%, and 32.6% of cases, respectively. Delirium alone or in combination
with other symptoms was the most frequent indication to begin PS. Midazolam
was the most frequently used drug to initiate PS (98%), at a mean dose of
28.1 mg/day, in combination with parenteral morphine (84.7%) at a mean dose
of 25.4 mg/day. At the time of death, midazolam was administered in 98% of
patients (mean dose 22.3 mg/day), combined with parenteral morphine in 87.8%
of patients (mean dose 28.1 mg/day). Satisfaction for physicians and principal
caregivers after PS was good in 46 and 48 cases, respectively.
Conclusion. PS at home seems to be a feasible treatment option among selected
patients and makes a potentially important contribution to improving care for
those who choose to die at home. J Pain Symptom Manage 2012;43:1126e1130.
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Some terminally ill patients with cancer near
the end of life may experience intolerable suf-
fering refractory to targeted palliative thera-
pies. The home setting has been reported to
be preferred by most patients and relatives
and seems to be the favorite place of death.1
Admission to hospital or staying at home in
this period depends on many different factors,
including resource availability and personal
preference, other than clinical needs.2 It is
likely that hospitalized patients tend to have
a greater symptom burden than those who re-
main at home. Home care may offer a better
environment, limiting the occurrence of dis-
orientation and delirium.3 However, a distress-
ing death may be of concern for the family.
Palliative sedation (PS) is a common proce-
dure in palliative care that has caught the at-
tention of several authors and investigation
groups in the last years. According to recent
definitions, PS is the use of a nonopioid seda-
tive medication to relieve intolerable suffering
in the last days of life.4,5 PS is considered to be
an effective treatment modality for refractory
symptoms when aggressive efforts fail to pro-
vide relief in terminally ill patients with
cancer.6
Although in one study the frequency of PS
at home was higher than that reported in hos-
pital (36% vs. 21%), only 36% of patients who
were followed by the palliative care team died
at home.7 In another study of advanced can-
cer patients followed at home, more patients
were sedated when moved to hospital than
when remaining at home (32% vs. 23%).8 In
a systematic review of PS at home, only six pa-
pers reported data regarding patients who
were sedated at home. However, data report-
ing indications, mean duration, and drug
used for PS were not available or clearly out-
lined, and no a priori definition of PS was
adopted.9
The Home CaredItaly Group recently has
been established with the intent to report the
information on cancer patients followed at
home, given the paucity of existing data in
this setting. The aim of this multicenter study
was to retrospectively analyze the frequency,
the indications, and the modalities of PS at
home, in a consecutive sample of patients fol-
lowed by three home care units in Italy.The study was conducted in three home
palliative care units (HPCUs). The activities
of these groups in three areas of Italy have
been described elsewhere. The three palliative
home care programs that participated in the
study provide similar levels of assistance, with
visits ranging between two to three per week
for physicians and three to seven per week
for nurses, in addition to providing on-call
visits in case of need.10
Themedical charts of all consecutive patients
who received assistance from an HCPU in a six-
month period were reviewed. Patients who died
at homeduring this periodwere included in the
study. A physician was trained to collect and en-
ter data into a standardizeddata sheet. From the
medical chart review, all patients who were ad-
ministered ‘‘specific sedatives to relieve intoler-
able suffering from refractory symptoms by
reducing a patient’s level of consciousness
with nonopioid sedative medication in the last
days of life’’ were selected and considered as pa-
tients receiving PS.9 The characteristics of this
groupof patients were analyzed, as well as the in-
dications to start PS, the duration, and thedrugs
and their doses used at the beginning of PS and
at the time of death. Involvement of relatives in
the decision-making process also was retrieved
from the charts when available, and whether
physicians and relatives were satisfied with the
efficacy and the purpose of the treatment.
Statistical Analysis
Collected data were analyzed using SPSS Soft-
ware v.14.0 (SPSS, Inc., Chicago, IL). Descrip-
tive summaries for all measures are reported
as means and standard deviations (SD) for nu-
meric variables, and as percentages for categor-
ical variables. Statistical analysis of quantitative
data, including descriptive statistics, was per-
formed for all items. The Chi-squared test was
used to make comparisons with respect to cate-
gorical variables, and Fisher’s exact test was
used if sample size criteria were not met for
Chi-squared approximation. The paired sam-
ples Student’s t-test was used to compare mean
doses at the different intervals. The one-way
analysis of variance was used for parametric
analysis. All P-values were two-sided and P-
values less than 0.05 were considered to indi-
cate statistical significance.
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The medical charts of 370 consecutive pa-
tients who died at home were examined.
Forty-nine patients (13.2%) received PS before
dying, according to the definition stated in the
Methods. Thirty-three patients were male. The
mean age was 72.3 (SD 12) years, and the pri-
mary diagnoses in rank order were gastrointes-
tinal cancer (n¼ 13), lung cancer (n¼ 12),
genitourinary cancer (n¼ 10), and other
(n¼ 14).
Age and gender did not influence the pa-
rameters examined. PS was proposed by the
team, relatives, or both in 63.3%, 4.1%, and
32.6% of cases, respectively. No differences in
survival between patients who were sedated
and those not sedated were found (P¼ 0.98).
The mean survival in sedated and not sedated
patients was 38 and 35 days, respectively. No re-
lationship between relatives’ involvement and
specific symptoms requiring PS was found
(P¼ 0.975). In two cases, PS was requested by
the patients themselves (4.1%). PS was never
discontinued for any reason. Duration of PS
was 86 (SD 242) hours. Delirium alone or
in combination with other symptoms was the
most frequent indication to begin PS. The
symptoms that prompted PS initiation are
listed in Table 1.
Opioids (parenteral morphine) were star-
ted in 41 patients (84.7%) at mean doses of
25.4 mg/day (SD 19.6). Most patients al-
ready were receiving opioids for pain manage-
ment and were continued or converted to the
parenteral route. Nineteen of 21 patients with
dyspnea were given opioids. No differences in
use and doses of opioids were found when
compared with patients who received PS andTable 1
Indications to Start PS
Reasons to Start PS Frequency Percentage
Delirium 26 53.1
Delirium/pain 1 2
Delirium/dyspnea 7 14.3
Dyspnea 10 20.4
Dyspnea/O 1 2
Pain 1 2
Pain/dyspnea 2 4.1
Pain/dyspnea/psychological
distress
1 2
Total 49 100
PS¼ palliative sedation; O¼ other.did not have dyspnea (P¼ 0.781). Midazolam
was started in 48 patients (98%) at mean doses
of 28.1 mg/day (SD 2 2.08). Haloperidol was
started in seven patients (14.3%) at mean
doses of 2.8 mg.
At time of death, parenteral morphine was
administered in 43 patients (87.8%) in mean
doses of 28.1 mg/day (SD 20.8), and mida-
zolam was administered in 48 patients (98%)
at mean doses of 22.3 mg/day (SD 12.5).
No differences between starting and final
doses of both drugs were found (P¼ 0.374).
Neuroleptics, including chlorpromazine and
promethazine, were given in two and four pa-
tients, respectively.
The level of satisfaction for physicians and
principal caregivers after PS was good in 46
and 48 cases, respectively. In no cases were rel-
atives unsatisfied with the treatment, and only
in one case did the physician consider PS un-
satisfactory. In two cases, this information was
unavailable from the chart review.Discussion
Results from this retrospective analysis of
data regarding patients who were sedated at
home before dying provide interesting in-
formation. Each HCPU used the same defini-
tion for PS. PS was found to be an effective
method to relieve terminal suffering in the
last days of a dying patient, especially for rela-
tives who considered PS effective and were sat-
isfied with the treatment. The need to begin
PS was carefully explained, as evidenced in
the clinical notes, and in about one-third of
cases, the decision was made by the patient’s
relatives.
Data gathered from this study indicate a fre-
quency of PS of 13.2%, which is lower than
that found in a previous study of how cancer
patients die at home (35%). This finding
could be attributed to the different time
periods examined and the number of units
included in the survey, and the use of a
different definition of PS.10 Different frequen-
cies of PS performed at home have been re-
ported in the literature.9 The large variability
observed in the use of PS among centers sug-
gests a lack of appropriate criteria adopted
for definition of PS. For example, in a multi-
center Italian study, the ranges varied between
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of consensus on definition of PS among the
centers involved.11 The frequency found in
the present study also seems to be lower than
the 20%e50% rate reported by hospital-
based palliative care units or hospice,12e15
with the highest rate in acute care units.16 It
is likely that hospitalized patients tend to
have a greater symptom burden than those
who remain at home or patients are admitted
to hospital as an emergency because of the de-
velopment of refractory symptoms close to
death.7,8 Finally, the different environment at
home could potentially influence the decision
to start PS; factors include lack of a continuous
bedside presence, family cooperation, time for
planning, and decision making in case of an
emergency.9
The principal symptom to be relieved with PS
was delirium; alone or in combination with
other symptoms, it was the indication for PS
in about 70% of patients. This confirms recent
data in the home care setting3,7,17 and in a pio-
neer study,8 and is similar to data reported in
a palliative care unit population.16 Dyspnea
was the second most frequent reason to start
PS (about 43% of patients). Similar to other
studies, delirium and dyspnea combined were
also a most frequent indication for PS.3,17 Dys-
pnea (52%), pain (49%), and delirium (17%)
in different combinations weremore frequently
reported in a pioneer study as an indication for
PS,8 whereas in two other Italian studies, per-
centages were not reported.11,18 Pain seems to
be a relatively infrequent indication for PS, re-
flecting other recent experiences;3,7 this differs
from the early study, where drowsiness was not
clearly distinguished from PS,8 and a more re-
cent study performed in Israel, where uncon-
trolled pain was deemed to require PS at the
end of life in more than half of patients fol-
lowed at home.17 It is likely that an unclear def-
inition of PS, including, for example, the use of
opioids for sedating patients for pain relief, bi-
ased these data. This is confirmed by the use
of increasing doses of opioids, given alone, to
achieve PS.17 In the present study, doses of opi-
oids remained relatively stable, as did doses of
midazolam. Morphine, converted to the paren-
teral route, was, inmost cases, a continuation of
the previous treatment for pain.
Midazolam was the drug most frequently
used to begin and maintain PS for almost allpatients. This drug preference also was re-
ported in another retrospective analysis of
patients who died at home.3 Similarly, doses
of midazolam did not change significantly
until death; this differs from data found in
patients followed on an acute care unit.16 It
is likely that patients admitted in such units
may have more intense distressing symptoms
or may be receiving large amounts of other
drugs prescribed previously. However, doses
of midazolam were lower than those reported
(about 60e100 mg/day) in a similar retrospec-
tive study performed in a single institution in
Spain.3
Duration of sedation was in the range of pre-
vious experience (more than 72 hours) when
compared with previous experiences at home
where duration of PS largely varied, ranging
from one day or less to 13 days, with an average
duration of two to three days.9
No differences in survival were evident be-
tween patients who received PS and patients
who did not undergo this treatment. This was
similar to the results reported in other studies
performed at home,3,7,18 confirming that both
the aim and the effect of PS do not result in
shortening survival when used to relieve refrac-
tory symptoms.15
Finally, both physicians and relatives were sat-
isfied with the treatment, and in many cases,
relatives asked to start PS before a team mem-
ber could propose it, suggesting that the deci-
sion was shared to a great degree with the
team members and an agreement was clearly
achieved before starting PS. In a web-based
structured questionnaire, PS was considered in-
sufficiently effective by 42% of home care
nurses. However, these data expressed just an
opinion rather than raw data.19
Informed consent was obtained from pa-
tients or relatives after an agreement among
staff members was achieved.7 Verbal informed
consent to initiate PS was received directly
from patients deemed to be competent or
from their immediate family member.17 How-
ever, in a large Italian study, 62% of the sedated
patients at home had not been informed, and
data regarding relatives were unavailable.18
More awareness of prognosis was found in pa-
tients who were sedated before death, and the
decision to start sedation was made with the pa-
tient in 45% of cases.3 In previous experiences
at home, no formal evaluation and outcomes of
1130 Vol. 43 No. 6 June 2012Mercadante et al.PS have been reported.9 Marked and good im-
provement in symptom control was achieved
in 61% and 17% of patients, respectively.17
Data gathered from this study have the obvi-
ous limitations as a result of its retrospective
nature. However, the data set was simple and
the standardized checklist minimized data
missed, as demonstrated by data retrieved
and available for analysis.
PS appears to be a feasible treatment at
home. This treatment was considered safe and
effective by both team members and relatives,
who shared the decision to relieve intractable
symptoms at the end of life and achieve a peace-
ful death for the patient.Disclosures and Acknowledgments
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